Inspite of achieving an entire response with best induction therapy, nominal residual disorder frequently persists, necessitating consolidation therapy to mitigate the risk of relapse by eradicating residual sickness. In patients who have gained seven+3 induction therapy, consolidation therapy is initiated with high-dose cytarabine, often called H